At present, there are two groups of P2Y12 antagonists (Figure 2) which, after aspirin, are the most widely prescribed antiplatelet agents in CVD. Thienopyridines, including ticlopidine, clopidogrel, and prasugrel, irreversibly inhibit P2Y12R upon metabolic conversion into active metabolites by the hepatic cytochrome P-450 system (Cattaneo, 2010; Schrör et al., 2012). On the other hand, ticagrelor, cangrelor, and elinogrel reversibly and directly bind the receptor without any need for bioactivation (Cattaneo, 2010; Schrör et al., 2012) (Figure 2).